Citigroup’s Acceleron Pharma XLRN Stock Holding History

Citigroup’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,200	Closed	-$198K	–	7763
2020 Q1	$198K	Hold	2,200	–	–	﹤0.01%	4756
2019 Q4	$117K	Sell	2,200 -7,700	-78%	-$351K	﹤0.01%	5631
2019 Q3	$391K	Buy	9,900 +1,200	+14%	+$52.1K	﹤0.01%	4576
2019 Q2	$357K	Buy	8,700 +5,700	+190%	+$236K	﹤0.01%	4764
2019 Q1	$140K	Sell	3,000 -3,900	-57%	-$171K	﹤0.01%	5440
2018 Q4	$300K	Buy	6,900 +3,100	+82%	+$155K	﹤0.01%	4626
2018 Q3	$217K	Buy	+3,800	New	+$187K	﹤0.01%	5168
2017 Q1	–	Sell	-9,300	Closed	-$237K	–	7405
2016 Q4	$237K	Buy	+9,300	New	+$295K	﹤0.01%	5137

Citigroup's XLRN Position: Q4 2021 in Review

Citigroup sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 248,768 shares — an estimated $42.8M sold.

Citigroup first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $42.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Citigroup reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Citigroup sold 248,768 Acceleron Pharma shares in Q4 2021, an estimated $42.8M.
Citigroup first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
Citigroup's Acceleron Pharma position peaked at $42.8M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.